Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Second Quarter of Fiscal 2026 Ended December 31, 2025

Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Second Quarter of Fiscal 2026 Ended December 31, 2025

SHANGHAI, March 23, 2026 /PRNewswire/ -- Gamehaus Holdings Inc. ("Gamehaus" or the "Company") (Nasdaq: GMHS), a technology-driven mobile game publisher, today announced its unaudited financial results for the second quarter of fiscal year 2026 ended...

Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study

Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study

SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...

RyzoBee Announces Root Series Kickstarter Launch Planned for Q2 2026, Bringing Modular RootMaker Electronics to Makers and 3D Printing Creators in North America and Europe

RyzoBee Announces Root Series Kickstarter Launch Planned for Q2 2026, Bringing Modular RootMaker Electronics to Makers and 3D Printing Creators in North America and Europe

HONG KONG, March 21, 2026 /PRNewswire/ -- RyzoBee today announced that its Root Series is planned to launch on Kickstarter in Q2 2026 for the North American and European markets (timing subject to confirmation). In response to growing...

Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon2

Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon2

Treatment with ZEGFROVY ® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful...

FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results

FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results

Full-Year Revenue Growth of 867.9% Year-over-Year Achieved Net Income Turnaround in Fiscal Year 2025 HONG KONG, March 21, 2026 /PRNewswire/ -- FiEE, Inc. (NASDAQ:FIEE) ("FiEE" or the "Company"), a technology company integrating IoT, connectivity and...

Ten Pao Group Announces 2025 Annual Results

Ten Pao Group Announces 2025 Annual Results

Revenue Increased 3.2% to HK$5,558.6 million, with Rising Dividend Payout to 34.7% Industrial and Consumer Power Supply Businesses Recorded Solid Growth, Supported by Expanding Global Manufacturing Capabilities Financial highlights For the year...

Everbright Environment Announces 2025 Annual Results

Everbright Environment Announces 2025 Annual Results

HONG KONG, March 20, 2026 /PRNewswire/ -- China Everbright Environment Group Limited ("Everbright Environment" or the "Company") (257.HK) announces the consolidated results of the Company and its subsidiaries (collectively the "Group") for the year...

CNOOC Limited Announces Huang Yongzhang as Chief Executive Officer

CNOOC Limited Announces Huang Yongzhang as Chief Executive Officer

HONG KONG, March 20, 2026 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces today that Mr. Huang Yongzhang has been appointed as the Vice Chairman, an Executive Director, the...

Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development

Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development

WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised $787 million in financing rounds. The investment included participation by a...

Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability

Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability

SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 45
  • menu
    menu